Circulating tumor DNA dynamics on front-line chemotherapy with bevacizumab or cetuximab in metastatic colorectal cancer: A biomarker analysis for acquired genomic alterations in CALGB/SWOG 80405 (Alliance) randomized trial.

Authors

Kanwal Pratap Singh Raghav

University of Texas MD Anderson Cancer Center, Houston, TX

Kanwal Pratap Singh Raghav , Fang-Shu Ou , Alan P. Venook , Federico Innocenti , Ryan Sun , Heinz-Josef Lenz , Scott Kopetz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2022 ASCO Gastrointestinal Cancers Symposium

bookmark_border

BREAKWATER safety lead-in (SLI): Encorafenib + cetuximab (EC) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAF^V600E) metastatic colorectal cancer (mCRC).

First Author: Scott Kopetz

insert_chart_outlined

Poster

2022 ASCO Gastrointestinal Cancers Symposium

bookmark_border

BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC).

First Author: Scott Kopetz

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAF^V600E) metastatic colorectal cancer (mCRC).

First Author: Scott Kopetz

insert_chart_outlined

Poster

2017 Gastrointestinal Cancers Symposium

bookmark_border

Parallel sequencing of a 50 genes panel in metastatic colorectal cancer (MCRC) patients (pts) treated with intensive first-line FIr-B/FOx triplet chemotherapy plus bevacizumab (BEV): Preliminary data and clinical outcome.

First Author: Gemma Bruera